What are the drug options for Vasoactive Intestinal Peptide (VIP) receptor antagonists?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vasoactive Intestinal Peptide (VIP) Receptor Antagonists: Drug Options

The primary VIP receptor antagonist drug option is VIP(10-28), a 19-amino acid carboxyl terminus fragment of VIP that functions as a competitive antagonist at VIP receptors without activating adenylate cyclase. 1

Mechanism and Characteristics of VIP Receptor Antagonists

  • VIP(10-28) inhibits binding of VIP to receptors in cancer cell lines and membrane preparations, confirming its antagonistic properties 1
  • This fragment lacks intrinsic activity (does not stimulate cyclic AMP synthesis) but competitively blocks the effects of full VIP agonists 1
  • PG 97-269 is another VIP receptor antagonist that shows high affinity and selectivity for the VPAC1 receptor subtype expressed on gut epithelial cells 2

Clinical Applications of VIP Receptor Antagonists

  • PG 97-269 effectively inhibits VIP-induced secretory responses in both rat and human intestinal mucosa 2
  • VIP antagonists can block enterotoxin-induced secretion, suggesting potential applications in treating secretory diarrheas 2
  • A lipophilic VIP analog with antagonist properties, stearyl-Nle(17)-neurotensin(6-11)VIP(7-28) (SNH), has shown antiproliferative effects against cancer cell lines 3

Combination Therapy Potential

  • The lipophilic VIP antagonist SNH enhances the antiproliferative effects of various chemotherapeutic agents including:
    • Doxorubicin (antibiotic)
    • Vinorelbine (antimicrotubule agent)
    • Paclitaxel (antimicrotubule agent)
    • Gemcitabine (antimetabolite)
    • Irinotecan (topoisomerase I inhibitor)
    • Cisplatin (platinum compound) 3

Management of VIP-Related Conditions

  • For VIPomas (rare neuroendocrine tumors that secrete excessive VIP), octreotide is the primary pharmacological treatment rather than VIP antagonists 4
  • Octreotide effectively controls diarrhea associated with VIPomas by suppressing VIP secretion rather than antagonizing its receptors 4
  • Octreotide dosage can be titrated against VIP levels with normalization of levels as the target 4

Diagnostic Applications

  • Modified VIP peptides can be used for imaging tumors that express VIP receptors
  • Tc-99m-labeled VIP analog (TP 3654) has been used to successfully identify various cancers in humans 5

Challenges in VIP Antagonist Development

  • Despite promising preclinical results, VIP-based drugs (including antagonists) are not yet in clinical use due to:
    • Poor metabolic stability of peptide-based compounds
    • Limited penetration to desired sites of action 6
  • Development efforts continue to focus on creating more stable and selective VIP receptor antagonists 6

Future Directions

  • Combination of potent VIP antagonists with appropriate drug delivery systems may enhance therapeutic potential 6
  • Structure-activity relationship studies continue to identify more potent and selective VIP receptor antagonists 6
  • The potential regulatory role of proteolytically generated VIP fragments acting as endogenous antagonists warrants further investigation 1

References

4
Guideline

Treatment of Vasoactive Intestinal Peptide (VIP) Related Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5
Research

Imaging tumors in humans with Tc-99m-VIP.

Annals of the New York Academy of Sciences, 2000

Related Questions

What are the names of Vasoactive Intestinal Peptide (VIP) receptor antagonist drug options?
What is the equivalent dose of Concerta (methylphenidate) for a patient taking 10mg of Ritalin (methylphenidate)?
What is the recommended treatment for bacterial vaginosis?
Do I need to refer a patient with a RAD (Radiology Assessment Data) TI (Tissue Imaging) 4 finding for biopsy despite the radiologist's recommendation for a 1-year follow-up?
What are the first-line approaches for managing Dislipidemias, preventing atherosclerosis, and controlling risk factors in patients with Diabetes Mellitus?
What is the initial management for patients presenting with myocarditis, pericarditis, valvopathies, cardiac infiltrative diseases associated with aortic stenosis, and vasculitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question